CoChat

Changing use of antidiabetic drugs in the UK: trends in prescribing 2000–2017

Open access
Wilkinson, Samantha, Douglas, Ian, Stirnadel-Farrant, Heide, Fogarty, Damian, Pokrajac, Ana, Smeeth, Liam, Tomlinson, Laurie · 2018 · BMJ Open
Cited by 117

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Objectives: Guidelines for the use of drugs for type 2 diabetes mellitus (T2DM) have changed since 2000, and new classes of drug have been introduced. Our aim was to describe how drug choice at initiation and first stage of intensification have changed over this period, and to what extent prescribing was in accord with clinical guidelines, including adherence to recommendations regarding kidney function. Design: Repeated cross-sectional study. Setting: UK electronic primary care health records from the Clinical Practice Research Datalink. Participants: Adults initiating treatment with a drug for T2DM between January 2000 and July 2017. Primary and secondary outcome measures: The primary outcomes were the proportion of each class of T2DM drug prescribed for initiation and first-stage intensification in each year. We also examined drug prescribing by kidney function and country within the UK. Results: Of 280 241 people initiating treatment with T2DM drugs from 2000 to 2017, 73% (204 238/280 241) initiated metformin, 15% (42 288/280 241) a sulfonylurea, 5% (12 956/280 241) with metformin and sulfonylurea dual therapy and 7% (20 759/280 241) started other options. Clinicians have increasingly prescribed metformin at initiation: by 2017 this was 89% (2475/2778) of drug initiations. Among people with an estimated glomerular filtration rate of ≤30 mL/min/1.73 m 2, the most common drug at initiation was a sulfonylurea, 58% (659/1135). In 2000, sulfonylureas were the predominant drug at the first stage of drug intensification (87%, 534/615) but by 2017 this fell to 30% (355/1183) as the use of newer drug classes increased. In 2017, new prescriptions for dipeptidyl peptidase-4 inhibitors (DPP4i) and sodium/glucose cotransporter-2 inhibitors (SGLT2i) accounted for 42% (502/1183) and 22% (256/1183) of intensification drugs, respectively. Uptake of new classes differs by country with DPP4is and SGLT2is prescribed more in Northern Ireland and Wales than England or Scotland. Conclusions: Our findings show markedly changing prescribing patterns for T2DM between 2000 and 2017, largely consistent with clinical guidelines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2018-022768

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 117

Metadata

Authors
Wilkinson, S., Douglas, I., Stirnadel-Farrant, H., Fogarty, D., Pokrajac, A., Smeeth, L., & Tomlinson, L.
Venue
BMJ Open
Publisher
BMJ
Published
2018-07-28
Volume
8
Issue
7
Pages
e022768
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2884713629
Cited by
117
References
9
FWCI
8.53
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Changing use of antidiabetic drugs in the UK: trends in prescribing 2000–2017. https://app.cochat.ai/papers/10.1136/bmjopen-2018-022768
The paper
Wilkinson, S., Douglas, I., Stirnadel-Farrant, H., Fogarty, D., Pokrajac, A., Smeeth, L., & Tomlinson, L. (2018). Changing use of antidiabetic drugs in the UK: trends in prescribing 2000–2017. BMJ Open. https://doi.org/10.1136/bmjopen-2018-022768

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.